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Abstract
Background: Fosfomycin is increasingly called upon for the treatment of multi drug-resistant (MDR) organisms
causing urinary tract infection (UTI). We reviewed oral fosfomycin use for UTI treatment in a large UK hospital.
The primary goal was to audit our clinical practice against current national guidelines. Secondary aims were to
identify factors associated with treatment failure, and to investigate the potential for using fosfomycin in patients
with co-morbidities.
Methods: We retrospectively studied 75 adult patients with UTI who received 151 episodes of treatment with
fosfomycin from March 2013 to June 2015. We collected clinical data from our electronic patient record, and
microbiology data pre- and post- fosfomycin treatment. We recorded additional data for patients receiving
prolonged courses in order to make a preliminary assessment of safety and efficacy. We also reviewed >18,000
urinary tract isolates of Escherichia coli and Klebsiella spp. processed by our laboratory over the final year of our
study period to determine the prevalence of fosfomycin resistance.
Results: There was a significant increase in fosfomycin treatment episodes over the course of the study period.
Co-morbidities were present in 71 % of patients. The majority had E. coli infection (69 %), of which 59 % were
extended spectrum beta-lactamase (ESBL)-producers. Klebsiella infections were more likely than E. coli to fail
treatment, and more likely to be reported as fosfomycin resistant in cases of relapse following treatment. There
were no adverse events in five patients treated with prolonged fosfomycin. Among all urinary isolates collected
over a year, fosfomycin resistance was documented in 1 % of E. coli vs. 19 % of Klebsiella spp. (p < 0.0001).
Conclusions: We report an important role for oral fosfomycin for MDR UTI treatment in a UK hospital population,
and based on the findings from this study, we present our own local guidelines for its use. We present preliminary
data suggesting that fosfomycin is safe and effective for use in patients with complex comorbidities and over
prolonged time periods, but may be less effective against Klebsiella than E. coli.
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Background
Urinary tract infections (UTI) are common and account
for a significant burden of hospital admissions and asso-
ciated healthcare expenditure [1]. Treatment has become
more challenging due to an ageing population, high
rates of comorbid disease and polypharmacy, allergy or
intolerance to antimicrobial drugs, a growing number of
patients with underlying immunological or anatomical
defects, and the increasing prevalence of multi-drug
resistant pathogens [1, 2]. Re-evaluation of ‘neglected’
antibacterial drugs is one approach to tackling this
complicated burden of disease [3, 4]. One such agent,
fosfomycin, is being called back into play in the UK for
treating UTI [5, 6].
Characteristics that make fosfomycin appealing for
the treatment of UTI include rapid absorption after oral
administration, concentration for excretion in urine,
biofilm activity [7, 8], and its efficacy against many
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multi-drug resistant organisms, including extended
spectrum beta-lactamase (ESBL) and AmpC-producing
Enterobacteriaceae [9]. Oral fosfomycin is well tolerated
and largely free of serious adverse effects [10, 11], with
only 5 % of patients reporting side-effects, most com-
monly diarrhoea [12].
Until recently, the only preparation of fosfomycin
available in the UK was unlicensed Monuril (fosfomycin
trometamol) imported from Germany. However, a li-
censed product has now become available (Mercury
Pharmaceuticals). National guidelines have been pub-
lished by two UK agencies, NICE (National Institute for
Health and Care Excellence) and PHE (Public Health
England); fosfomycin is recommended for uncompli-
cated UTI (defined as no fever/flank pain) caused by
ESBL-producing E. coli in adults, if the prescription is
endorsed by a microbiologist [13–15].
Approaches to dosing vary: NICE guidelines suggest
a single dose of 3 g in women and two 3 g doses
(at an interval of 3 days) in men [14], but the UK
product licence is for a single dose only and European
guidelines produced by the European Association of
Urology do not recommend fosfomycin for use in men
at all [16]. Although the UK recommendation is
restricted to uncomplicated lower UTI [3, 14, 17, 18],
and the focus of existing guidance is for out-patient
treatment, fosfomycin has also been used with some
success in patients with risk factors for persistent or
recurrent UTI [11, 12, 19].
Nitrofurantoin is a potential alternative treatment
for UTI caused by MDR E. coli [13], but is not rec-
ommended in the third trimester of pregnancy, and
should be used with caution in patients with signifi-
cant renal impairment. Guidance on the estimated
glomerular filtration rate (eGFR) threshold for use has
varied, generally being set at 45 ml/min, but also
sanctioned for use in certain circumstances down to
30 ml/min [20]. Pivmecillinam is another potential
choice of oral agent, but susceptibility testing has only
recently been introduced in our institution, and was not
in routine use until after the time period described by
this study.
We retrospectively studied the use of fosfomycin in
our large teaching hospital by auditing local prescribing
against existing guidelines [14, 16], with the primary aim
of developing a clear picture of the context in which this
agent is currently used, and identifying ways in which
prescribing can be optimized. Secondly, having identified
a small group of patients receiving prolonged or
recurrent treatment, we scrutinized these cases to gain
insights into special situations that are not covered by
current guidance, but in which fosfomycin may have a
useful role. Finally, within the constraints of a retro-
spective study, we sought to identify preliminary
evidence for factors predictive of treatment failure, in




We undertook a retrospective observational study of oral
fosfomycin use for UTI. We included all episodes of oral
fosfomycin use for the treatment of UTI in adults
age ≥16 years, from March 2013 (when this agent
was first added to our local formulary) through to the
end of June 2015, irrespective of urine culture results.
Characteristics of patient cohort
The study centre is a large tertiary referral teaching
hospital in Oxfordshire, UK, with >1400 in-patient beds
serving a population of 805,000 (http://www.ouh.nhs.uk).
Our population of individuals with complex, recurrent,
resistant or persistent UTI is inflated by a tertiary
referral service for urology, a large renal dialysis unit,
and a regional renal transplant unit.
This cohort represents a group of patients who were
all deemed well enough to receive treatment with an oral
antibacterial agent. Routine clinical practice would be to
admit any patient unwell with signs of systemic sepsis or
clinical suspicion of pyelonephritis for monitoring,
imaging, and treatment with intravenous antimicrobial
therapy (this is a clinical assessment based on the whole
picture, but would hinge on features such as fever >38 °C,
tachycardia, hypotension, loin or back pain, and raised
inflammatory markers).
We identified fosfomycin treatment episodes retro-
spectively using electronic records held by pharmacy.
Based on the complex and changing product licence of
fosfomycin, as well as recommendations made by NICE
guidelines [14], local policy is that all fosfomycin prescrip-
tions should be authorized by the infectious diseases/
microbiology team. During the period of this study,
general practitioners were not able to access fosfomycin,
so all prescriptions were generated by hospital clinicians.
Our practice is to give oral fosfomycin as monotherapy
for UTI treatment.
Data collection methods
We collected data on patient demographics, co-morbid
diagnoses and laboratory parameters from the hospital
electronic patient record (EPR, Powerchart), and culture
results from electronic microbiology records (Sunquest).
We were unable to gain access to sufficient paper
records to review in detail the clinical symptoms at the
time of every treatment episode. However, in the five
patients who each received >10 fosfomycin doses, we
did obtain paper-based clinical notes as an additional
source of information.
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Analysis of fosfomycin resistance
In order to develop an overview of fosfomycin resistance
in our region, we also reviewed antibacterial susceptibil-
ity data from E. coli and Klebsiella spp. isolated from all
urine cultures processed by our laboratory during the
final twelve-month period of our study. These represent
unselected samples submitted from both primary and
secondary care settings. We focused our analysis on
these two organisms as they collectively account for >80 %
of UTIs treated with fosfomycin (see ‘Microbiology of
UTI treated with fosfomycin’ in results).
Standards for evaluation of prescribing
We used guidance published by Public Health England
(PHE) [15] and NICE [14] as standards against which to
evaluate our own prescribing.
Laboratory methods
Antimicrobial susceptibilities for uropathogens were
determined using the BD Phoenix Automated Micro-
biology System (Becton Dickinson, Franklin Lakes, New
Jersey; NMIC-75 panel. For fosfomycin, this contains
Glucose-6-Phosphate). BD Phoenix utilises an optimised
colorimetric redox indicator to detect active growth of
an organism in the presence of the antimicrobial. The
organism to be tested is grown on a non-selective
medium in appropriate conditions (37 °C in O2 for E.
coli / Klebsiella spp.) for 16–18 h, before a 0.5 MacFar-
land suspension is prepared (BD AutoPrep). This sus-
pension is inoculated into the appropriate antimicrobial
susceptibility testing panel (gram negative NMIC-75)
that contains microwells pre-lined with increasing con-
centrations of antimicrobial. The panel is incubated at
35 °C on the instrument for up to 16 h, and automatic-
ally read every 20 min for growth. The MIC (minimum
inhibitory concentration) for each antimicrobial is then
determined by the concentration at which the organism
fails to grow. The breakpoint for fosfomycin susceptibility
was ≤32 mg/L for oral treatment of uncomplicated UTI
based on breakpoint data published both by the European
Committee for Antimicrobial Susceptibility Testing
(EUCAST), available on-line at www.eucast.org, and the
British Society for Antimicrobial Chemotherapy (BSAC)
Standing Committee on Susceptibility Testing, available
on line at http://bsac.org.uk.
ESBL-production was detected by BD Phoenix. For E.
coli and Klebsiella pneumoniae, ESBL-positivity is reported
based on an ESBL test (a differential response between the
inhibitory effect of 2nd/3rd generation cephalosporins used
alone or in combination with clavulanic acid) and/or an
ESBL phenotypic pattern (resistance to piperacillin in
combination with resistance to any of the ESBL screening
drugs, cefotaxime, ceftriaxone, ceftazidime, cefpodoxime or
aztreonam in organisms that are carbapenem-susceptible).
Other oral antibacterial agents for which susceptibility
was routinely tested include amoxicillin, co-amoxiclav
(amoxicillin/clavulanate), cephalexin, trimethoprim, nitro-
furantoin and ciprofloxacin. During the study period,
our laboratory did not routinely test susceptibility to
pivmecillinam.
Definitions for treatment outcome
Due to the retrospective, observational approach, this
study was not designed to provide robust assessment of
clinical cure. However we set out to interrogate the
microbiology dataset for any preliminary evidence of
outcome following fosfomycin treatment.
We divided the potential laboratory outcomes into the
following five endpoint categories:
(i) No follow-up sample available;
(ii) Sterile urine;
(iii) Isolation of an indistinguishable organism compared
to pre-treatment cultures (may represent relapse);
(iv) Isolation of a different organism compared to
pre-treatment cultures (may represent re-infection);
(v) Mixed growth (may represent either a contaminated
sample, or relapse/re-infection).
We used these five endpoints to group patients into the
following two broad outcome categories:
(a) ‘Microbiological cure’ was our stringent cure definition,
classifying only individuals for whom there was a sterile
urine sample following their treatment episode as being
cured (endpoint (ii) from the list above).
(b) ‘Functional cure’ was a more relaxed definition.
Those classified as ‘cured’ in this case included
those with microbiological cure as defined above
(endpoint (ii)), but was also expanded to include
patients for whom there was no follow-up sample
(endpoint (i), suggesting likely clinical cure).
We excluded analysis of those for whom repeat cultures
showed either pure growth of a different organism from
baseline (endpoint (iv)) or mixed growth (endpoint (v)).
This approach was based on the rationale that in patients
with a different organism at follow-up, re-infection is the
most likely explanation. This scenario is not suggestive of
failure of index treatment with fosfomycin (and is rather a
marker of the nature of this cohort in which patients have
complex underlying reasons for recurrence of UTI, that is
not related to failure of the antibacterial agent). Mixed
cultures are of uncertain significance, potentially repre-
senting contamination of the urine sample, or recurrent
infection with more than one organism; neither of
these outcomes can be regarded as robust evidence of
fosfomycin failure.
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Data analysis
We recorded and analysed our data in a Microsoft
Excel spreadsheet (Microsoft 2011; v14.5.7). Additional
analysis was undertaken using Prism v6.0f, and on-line
at http://graphpad.com. We used open access regres-
sion analysis tools in Google sheets (https://docs.google.
com/spreadsheets) to produce Fig. 1.
For univariate analysis of factors associated with
cure, we used the Mann–Whitney U-test to assess the
statistical significance of differences between groups
for continuous variables, and Chi-square/Fisher’s
Exact Test for categorical variables (depending on
sample size).
For multivariate analysis, we selected variables to
enter based on those reaching statistical significance
at univariate level (Klebsiella infections) and vari-
ables that we predicted a priori to predict fosfomy-
cin treatment failure, namely in vitro fosfomycin
resistance, creatinine clearance and comorbidity.
Analysis was undertaken using a logistic regression
approach in Google sheets (https://docs.google.com/
spreadsheets).
Study approval
This study was registered and approved by the Audit
Department at Oxford University Hospitals NHS
Foundation Trust. Informed consent was not deemed
to be required.
Results
Characteristics of patient cohort
During the study period, 75 patients received oral
fosfomycin, undergoing 151 treatment episodes (for raw
data, see Additional file 1). There was a significant
increase in fosfomycin prescriptions by month over the
time period studied (Fig. 1). Females outnumbered males
(57 vs. 18). The median age was 73 years (IQR 55–80;
range 16–94), with no difference in age according to sex
(p = 0.7, Mann Whitney U test).
Co-morbidities or risk factors for UTI were present in
52/75 patients (71 %), most commonly underlying renal
tract disease (Table 1). eGFR was ≥10 mL / min in all
patients. There was documented evidence of input from
the microbiology/infectious diseases team in the EPR
for 57/75 (76 %) index treatment episodes.
Microbiology of UTI treated with fosfomycin
We analysed microbiology data initially focusing just on
the first treatment episode for each patient. The majority
had urine cultures positive for E. coli (52/75, 69 %;
Table 2). ESBL-production was reported in 31/52 of the
E. coli isolates (59 %) and 6/9 K. pneumoniae (67 %);
(Table 2). Overall, therefore, only 31/75 (41 %) of all
isolates met the microbiological criterion (ESBL E. coli)
for fosfomycin treatment stipulated by NICE guidance
[14]. This result reflects a discrepancy between our own
clinical practice and current guidelines.
Fig. 1 Number of fosfomycin treatment episodes by month in a cohort of adults treated for UTI in a UK teaching hospital. Each data point
represents the number of unique fosfomycin prescriptions (irrespective of total dose) issued each month, from the time fosfomycin was first
introduced to our formulary (March 2013) over 27 months to the end of the study period (May 2015). The solid line represents the trend
computed by linear regression (slope = 0.46, 95 % CI 0.31-0.62, R2 = 0.6, p < 0.0001); the dashed lines indicate 95 % confidence intervals around
the regression line
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Unexpectedly, fosfomycin was prescribed for two
patients with a urinary isolate that was reported as
fosfomycin resistant in vitro; one of these was E. coli
and the other Enterobacter aerogenes. There were a
further two isolates for which an in vitro fosfomycin
susceptibility was not reported (both E. coli).
Treatment episodes and dose schedules
The majority of individuals (n = 53/75; 71 %) had just
one fosfomycin treatment episode during the study
period; eight patients had two treatment episodes and
fourteen patients received ≥3 treatment courses. There
was no relationship between age or sex and receipt of >1
treatment episode (p = 0.9 and p = 0.2, respectively).
NICE guidelines recommend a single dose of fosfomy-
cin for females, and two doses (off-licence) for males
[13, 15]. Among females in this study cohort, 45/57
(79 %) first treatment episodes adhered to the single
dose recommendation [13, 15] with the remaining 12
being prescribed two or three doses. In contrast, among
males, only 8/18 (44 %) received the recommended ≥2
doses. However, across all 151 treatment episodes, men
were more likely to be prescribed additional fosfomycin
doses (median 1 dose in women, versus median 3 doses
in men p < 0.0001; data not shown).
Potential for treatment with nitrofurantoin
Among index treatment episodes, 31/75 (41 %) patients
had an isolate that was nitrofurantoin susceptible; 30/31
of these were E. coli (Table 2). Among the 31 patients
with nitrofurantoin-susceptible isolates, 30 had con-
temporaneous measurement of renal function. Of
these 30, four were ineligible for nitrofurantoin due to
eGFR <30 mL/min, one was pregnant, and another had
previously failed to respond to nitrofurantoin. This
leaves a total of 24 individuals for whom there was no
documented contra-indication to nitrofurantoin, but
who received fosfomycin instead.
Prolonged or recurrent fosfomycin treatment
In five individuals, treatment with standard short-course
fosfomycin failed to sterilize the urinary tract, and longer
courses were used (Table 3). There were no documented
concerns about safety or tolerability, and infection was
either cured or suppressed sufficiently to keep the patient
out of hospital during the treatment course, although two
subsequently relapsed and have been re-treated.
Treatment outcomes
Although this study was not specifically designed to
ascertain outcomes, we sought preliminary evidence for
Table 1 Risk factors for urinary tract infection in a cohort of 75 adults treated with oral fosfomycin
Risk factor Number of cases
(% of all individuals treated)
GU tract pathology (stones, cancer of prostate/bladder/kidneys, urethral disease, self catheterisation) 25 (33.3)
Renal transplant 12 (16.0)
Systemic disease (non-renal tract malignancy, steroids, diabetes, cardiovascular disease, GI tract disease) 12 (16.0)
Pregnant 3 (4.0)
No documented risk factor(s) a 23 (30.7)
TOTAL 75
a No cases of recent urological intervention or patients with indwelling urethral catheters were identified on the basis of retrospective review of electronic records
Table 2 Urine culture results obtained at index episode of UTI in 75 adults treated with oral fosfomycin
Urine culture result Number
(% of all patients)a
Number with ESBL
(% of cases with this organism)b
Number nitrofurantoin sensitive
(% of cases with this organism)b
Number fosfomycin sensitive
(% of cases with this organism)b
Escherichia coli 52/75 (69.3) 31/52 (58.5) 30/52 (56.6) 49/50 (98.0)
Klebsiella pneumoniae 9/75 (12.0) 6/9 (66.7) 1/9 (11.1) 9/9 (100.0)
Other Enterobacteriaceae
in pure growth
6/75 (8.0) 0/6 (0) 0/6 (0) 5/6 (83.3)
Pseudomonas 1/75 (1.3) n/a n/a n/d
Mixed growth 4/75 (5.3) n/a n/a n/a
No significant growth 2/75 (2.7) n/a n/a n/a
No data 1/75 (1.3) n/a n/a n/a
Total 75/75 37/61 31/61 63/65
n/a not applicable, n/d no data
aThe denominator in this column is the total number of patients with a urinary isolate (n = 75)
bThe denominator in these columns is adjusted according to data availability / relevance. Note that fosfomycin susceptibility data were missing for two E. coli isolates
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the success of treatment, using two different definitions,
‘functional’ cure and ‘microbiological’ cure (see Methods).
Follow-up culture results were obtained at a median of
13 days following the first fosfomycin dose (range 2–241
days; IQR 7–40 days).
Follow-up outcomes based on urine cultures were
divided into five categories as follows: no follow-up
sample available (22/75; 29.3 %), sterile urine at follow-
up (21/75; 28 %), isolation of the same organism
compared to pre-treatment cultures (19/75; 25.3 %), isola-
tion of a different organism compared to pre-treatment
cultures (8/75, 10.6 %) and mixed growth (5/75; 6.6 %).
(i) Microbiological cure: Using this stringent definition
of cure, only 40/75 cases could be classified (the
remaining 35 either had no post-treatment culture
data (n = 22), had culture data more suggestive of
reinfection (n = 8), or a mixed/contaminated sample
(n = 5)). Of the 40 that could be classified (Table 4),
21 (53 %) met the criteria for cure, and no factor
was statistically associated with failure.
(ii) Functional cure: Among 75 index treatment
episodes, 61 patients could be classified using this
more relaxed cure definition (the remaining 14
were equivocal due to post-treatment urine culture
being unavailable (n = 1), growing a different organ-
ism (n = 8) or a mixed/contaminated sample (n = 5)).
Of these, 42/61 (69 %) were considered cured. The
only factor associated with failure on univariate
analysis was infection with K. pneumoniae (p = 0.03;
Table 4). This finding should be interpreted with
caution as statistical significance is lost when
correction for multiple comparisons is undertaken
(e.g. by a Bonferroni approach). However, undertaking
a multivariate approach to analysis again
demonstrated Klebsiella as a significant
predictor of treatment failure (p = 0.04; Table 5).
Selection of fosfomycin resistance within this cohort
On follow-up urine culture, there were 19 instances in
which the identification of the organism was the same as
that from pre-treatment culture. In five isolates that
had been fosfomycin susceptible at baseline, the
follow-up culture was reported fosfomycin resistant
(four Klebsiella pneumoniae and one Morganella mor-
ganii). Selection of resistance was significantly more
frequent in non-E. coli Enterobacteriaceae than in
E. coli (5/6 vs. 0/13; p = 0.0005).



















FOS015 80–89 M Vasculopath; bilateral below
knee amputations. Recurrent E.
coli bacteraemia with unclear
source despite extensive
investigation. Relapsed after a
treatment course of iv ertapenem





FOS038 60–69 M History of recurrent UTI for >
10 years. Dilatation for urethral
stricture, followed by TURP.
Prostate cancer confirmed;
treated post-op with radiotherapy





FOS060 60–69 M Relapsing urosepsis following
TRUS biopsy (negative for
prostate cancer). Presumed
prostatitis as focus of infection.











FOS098 70–79 M Transitional cell carcinoma
treated with nephrouretectomy.
Regular surveillance cystoscopy
complicated by recurrent UTI;
recurred after completing
treatment with meropenem.





FOS140 40–49 F Recurrent UTI following sling
procedure and botox treatment
for stress/urge incontinence.
Intermittent self-catheterisation.
Good symptomatic relief with
fosfomycin.





eGFR estimated glomerular filtration rate, TURP trans-urethral resection of the prostate, TRUS trans-rectal ultrasound guided prostate biopsy
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Fosfomycin resistance patterns in all urine isolates of
E. coli and Klebsiella
Of 18,474 urinary E. coli and Klebsiella spp. isolates
processed by our laboratory in the final twelve months
of the study, 511 were fosfomycin resistant (3 %). The
majority of these were Klebsiella spp. (363/1888 (19 %)
fosfomycin resistant, versus 148/16586 (1 %) for E. coli;
p < 0.0001). There was no relationship between ESBL-
production and fosfomycin resistance (data not shown).
Mortality
Our electronic patient record did not record any patient
deaths. However, this study was not designed to capture
mortality data robustly and we cannot exclude the
Table 5 Multivariate analysis of clinical and laboratory variables as predictors of outcome for fosfomycin treatment of urinary
tract infection in adults. Cure and fail are classified according to ‘functional’ definition (results presented in data columns 1–3) or
‘microbiological’ definition (results presented in data columns 4–6)
Predictor ‘Cure’ (functional
definition)
Total n = 33
‘Fail’ (functional
definition)






Total n = 20
‘Fail’ (microbiological
definition)




Fosfomycin resistant in vitro 1/33 1/19 0.21 0/20 1/19 0.99
Klebsiella pneumoniae 2/33 5/19 0.04 2/20 5/19 0.13
Comorbidity (any, including
transplant/urethral catheter)
21/33 14/19 0.22 15/20 14/19 0.47
Median eGFR, ml/min (IQR) 64 (41–86) 90 (29–90) 0.19 64 (37–87) 90 (29–90) 0.20
Total number of patients represented is 52 for functional cure (‘cure’ group (n = 33) is patients with a sterile urine on follow-up culture, or no follow-up culture;
‘fail’ group (n = 19) is patients with recurrent growth of an indistinguishable organism)
Total number of patients represented is 39 for microbiological cure (‘cure’ group (n = 20) is patients with a sterile urine on follow-up culture; ‘fail’ group (n = 19) is
patients with recurrent growth of an indistinguishable organism)
eGFR estimated glomerular filtration rate
Table 4 Univariate analysis of clinical and laboratory variables as predictors of outcome for fosfomycin treatment of urinary tract
infection in adults. Cure and fail are classified according to ‘functional’ definition (results presented in data columns 1–3) or
‘microbiological’ definition (results presented in data columns 4–6)
Predictor ‘Cure’
(functional definition)
Total n = 42
‘Fail’
(functional definition)






Total n = 21
‘Fail’
(microbiological definition)




ESBL-positive 20/37 10/19 1.0a 12/21 10/19 1a
Nitrofurantoin
resistant
17/37 12/19 0.3a 8/21 12/19 0.2a
Fosfomycin
resistant
1/35 1/19 1.0a 0/20 1/19 0.49a
Male 14/42 4/19 0.4a 4/21 4/19 0.72a
Klebsiella
pneumoniae
2/37 5/19 0.03a 2/21 5/19 0.22a
Comorbidity
(any)
32/42 15/19 1.0a 12/21 15/19 0.19a
Transplant 8/42 3/19 1.0a 4/21 3/19 1a
Urethral
catheter


































Total number of patients represented is 61 for functional cure (‘cure’ group (n = 42) is patients with a sterile urine on follow-up culture, or no follow-up culture; ‘fail’
group (n = 19) is patients with recurrent growth of an indistinguishable organism). Total number of patients is 40 for microbiological cure (‘cure’ group (n = 21) is patients
with a sterile urine on follow-up culture; ‘fail’ group (n = 19) is patients with recurrent growth of an indistinguishable organism)
The denominator in some rows is smaller than the overall total due to missing data, including no culture / susceptibility data and ESBL-status unknown or not applicable
eGFR estimated glomerular filtration rate, CRP C-reactive protein
aFisher’s Exact Test; b Mann Whitney U test
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possibility that patients referred for treatment from
outside our region may subsequently have died.
Discussion
As the global prevalence of drug resistance increases,
fosfomycin is likely to become increasingly called upon for
the oral treatment of UTI [21], as well as for other
infections of the urogenital tract including prostatitis [22].
This pattern is reflected in our own centre, in which we
show that fosfomycin prescriptions have increased over
time. Within the constraints of retrospective analysis, it is
difficult to be certain what underpins this change, but we
can postulate that the increase in treatment episodes is
most likely to reflect increased clinician awareness of
fosfomycin as a formulary agent, recognition of NICE
guidelines, and potentially an increase in the number of
patients presenting with MDR organisms over time.
Current NICE guidelines [14] are based on only four
small studies (for summary, see Additional file 2) of
which two were undertaken in Turkey, one in Spain and
one in North America [10, 11, 19, 23]. This cohort is
therefore a significant recent addition to the data, and
offers a unique snapshot of a UK population. A median
age of 73 is likely to reflect the increasing risk of UTI
with age [24], as well as the fact that co-morbid prob-
lems increase with age.
In our subgroup analysis, only 21 of 40 cases (53 %)
met our most stringent definition of cure. Notably, 22
cases were excluded from this analysis as there was no
follow-up data; this may well artificially lower the
proportion of cases that we were able to report as cured.
Low cure rates may also be a result of the complex
population described here (co-morbidity, older age,
urethral catheters), but due to small numbers none of
these factors was found to be independently predictive
of treatment failure (Table 4).
We identified several notable patterns in fosfomycin
prescribing and outcomes. Firstly, males were signifi-
cantly less likely to receive the recommended fosfomycin
treatment dose than females based on NICE guidance
[13]. Secondly, our data suggest a lower chance of cure
in UTI caused by Klebsiella spp., consistent with higher
local in vitro resistance rates, also observed elsewhere
[25–27]. Interestingly, however, the failure of fosfomycin
in this cohort occurred even with Klebsiella isolates that
were reported as fosfomycin susceptible pre-treatment.
In the absence of robust prospective data collection, we
can only speculate why fosfomycin might have been
used in two patients with an isolate reported as resistant
in vitro. The most likely explanations are that the
fosfomycin was prescribed prior to the full susceptibil-
ity data being released from the laboratory and/or the
patient had a previous urinary isolate that was reported
as fosfomycin susceptible.
Thirdly, this cohort is of particular interest in being
enriched for individuals with significant risk factors for
recurrent, resistant and difficult-to-treat UTI due to the
tertiary referral specialties in our centre. We did not find
any association between co-morbidities and increased
risk of treatment failure in this cohort. This is prelimin-
ary evidence that fosfomycin can be safe and effective
for treating UTI even in this complex group, although
larger numbers and prospective studies are needed to
assess this with greater confidence.
Finally, in this cohort, nearly one-third of patients were
potentially eligible for treatment with nitrofurantoin,
which is licensed, easier to access, and cheaper [14].
However, the retrospective approach to data collection
meant it was not possible to identify the proportion of
these patients in whom there was a contra-indication to
nitrofurantoin. Another alternative agent for the treatment
of urinary tract infection caused by ESBL-producing
Enterobacteriaceae is pivmecillinam [28], which may
increasingly be called into play.
Concerns regarding wider use of fosfomycin include
tolerability, cost, and the spread of resistance; we address
these issues here in turn.
Regarding tolerability, in our five patients who received
multiple fosfomycin doses, the clinical notes suggested the
drug was well tolerated. This is consistent with previous
reports [19, 22, 23, 29].
In terms of economic implications in the UK, a single
sachet of fosfomycin 3 g can currently cost £10-60
depending on the supply route (unlicensed or licensed
product) compared to an equivalent three day treatment
regimen with nitrofurantoin for which the total is < £3
[14]. Although nitrofurantoin is cheaper, there are
potential disadvantages, including uncommon (but po-
tentially serious) side effects, and the need for longer
courses (typically four times daily dosing for 3 to 5 days).
Alternative oral agents may have been possible in some
cases, but 31/75 patients in this cohort had no other oral
alternative. In these instances, fosfomycin saves the cost,
risks and time taken to provide intravenous therapy.
The issue of selection and spread of resistance is
complex [6, 16, 21, 30, 31]. Notably, in this study, the
post-treatment isolate in 5/19 cases of microbiological
failure was fosfomycin-resistant, all of which were non-E.
coli Enterobacteriaceae. Fosfomycin resistance can be caused
by a number of different mechanisms, including chromo-
somal mutations in genes encoding membrane transport
systems or regulators of these transporters (uhpA, uhpT,
glpT, ptsI), modification of murA (the drug’s target of
action), or the presence of catalytic enzymes encoded by fos
genes, some of which can be transferred on mobile genetic
elements [21, 30, 31]. A recent analysis reports a fosfomycin
resistance rate of 0.5 % in community-acquired E. coli UTI
in women in the UK [24]; it is unsurprising that our figure is
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higher (1 %) as this includes a hospital population at more
risk of MDR organisms.
Data from both in vitro and clinical studies suggest
that the emergence of resistance during treatment is
higher for Pseudomonas aeruginosa, Proteus, Klebsiella
and Enterobacter spp., as opposed to E. coli, [21, 27]
consistent with what we observed here, and suggesting
that fosfomycin should be used with caution in infec-
tions caused by these organisms.
In this current study, multivariate analysis is somewhat
limited by small patient numbers and by missing data
(due to the retrospective approach). Furthermore, the
selection of variables entered into a multivariate analysis
is characteristically based on those which reach statistical
significance at univariate level; in this case only Klebsiella
infection reached this threshold. Nevertheless, entering
factors that could reasonably be hypothesized to be pre-
dictive of treatment failure into multivariate analysis,
Klebsiella still emerged as significantly associated with
failure (p = 0.04). A small study from Hong Kong also
points to a higher rates of failure in Klebsiella compared
to E. coli UTI [27]. The benefits of more widespread use
of fosfomycin therefore have to be balanced against the
dual risks of increasing selection pressures for resistance,
and these preliminary data suggesting that it may be less
efficacious against Klebsiella infection, irrespective of in
vitro susceptibility.
There are several caveats and limitations to this study.
Although our cohort is larger than previous equivalent
studies (Additional file 1: Table S1), our power to derive
statistically significant findings is still limited by small
numbers of patients in each individual subgroup
(highlighted by the breakdown of characteristics presented
in Tables 1, 2, 4 and 5). Certain data (e.g. co-morbidities
and involvement of the microbiology team) may have
been under-reported in the EPR. We did not have access
to complete paper records for the full cohort, so we have
not been able to provide a detailed description of patient
symptoms at the outset of treatment. Thus we have not
been able to discriminate between asymptomatic bac-
teriuria and symptomatic UTI, or to identify features to
distinguish between upper and lower UTI.
The retrospective study design also made assessment of
clinical and microbiological end-points challenging, and
made it impossible to justify why fosfomycin was chosen
for treatment in each individual case. A related problem is
the tertiary referral nature of our centre, which means that
relevant culture data may have been generated elsewhere,
and this may have led to missing culture data at the outset
of treatment, and a potential over-estimation of cases of
functional cure. Further prospective studies are undoubt-
edly warranted to scrutinize prescribing and outcomes in
larger cohorts, to collect more complete and robust
clinical data and to provide a more reliable assessment of
final outcome, including seeking information from pri-
mary care regarding previous or subsequent courses of
antibacterial therapy. Those wishing to apply our conclu-
sions to their own centres should consider carefully the
extent to which the cohort and epidemiology described
here is comparable to their own patient populations.
Nevertheless, as a consequence of the data presented
here, we have reviewed our local approach to fosfomycin
prescribing, and have produced new guidelines with a view
to making our own use of fosfomycin more rational and
consistent. These include the following recommendations:
i. Use of an alternative oral agent, particularly
nitrofurantoin, should be considered first;
fosfomycin should only be used if other oral
options are contraindicated on the grounds of in
vitro susceptibility data or clinical factors
(drug allergy, pregnancy, renal impairment,
previous treatment failure);
ii. Fosfomycin may be used in patients with UTI
caused by non-E. coli Enterobacteriaceae, but only
after careful consideration, particularly considering
the potential risk of treatment failure for infection
caused by Klebsiella spp.;
iii. The number of doses of fosfomycin treatment
should be carefully considered: gender-based dosing
is suggested by NICE, although this approach is not
uniform. Additional doses may be used for patients
in whom eradication of infection is difficult.
iv. Underlying medical or surgical risk factors should
not be considered a contra-indication to treatment
with fosfomycin, and this preliminary evidence
suggests that prolonged courses are likely to be safe
and well tolerated; however, such patients need to be
kept under close expert review.
v. The optimum way to ensure that all of these factors
are considered is to reinforce the recommendation
that all individuals receiving oral fosfomycin are
discussed with the infectious diseases/microbiology
team. We have added fosfomycin to the electronic
guidelines available to clinicians via the ‘Microguide’
app (http://microguide.eu/).
vi. We have implemented a protocol for primary care
physicians to access fosfomycin for patients in the
community, following telephone or email approval
from a hospital microbiologist.
Conclusions
Overall, our findings underline the important role of
fosfomycin in the antibacterial armamentarium for
treatment of UTI. At present, the evidence of benefit is
strongest for E. coli infections, and careful stewardship is
important to reduce the risk of selection of antimicrobial
resistance. This study also provides preliminary data to
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suggest that prolonged courses of this drug are safe and
can be effective in suppressing or eradicating multi-
resistant organisms even in immunosuppressed patients
and in the setting of complex, abnormal renal tract
anatomy.
Additional files
Additional file 1: Spreadsheet reporting 75 unique patients treated with
fosfomycin for urinary tract infections. This excel file contains anonymised
details of 75 unique adult patients treated with fosfomycin for urinary tract
infections at Oxford University Hospitals NHS Foundation Trust from March
2013 through June 2015. Our original analysis also included patient sex,
but this has been removed from the suppl. data file in order to protect
anonymity. (XLSX 24 kb)
Additional file 2: Tabulated summary of studies that have informed
current NICE guidelines for fosfomycin use in UTI. This table contains a
brief summary of four studies from Europe/North America that are
referenced by current NICE guidelines regarding the use of oral
fosfomycin for treatment of UTI, including date of study, cohort
location, study design and cure data. (DOCX 88 kb)
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